5-Camp Battle Heating Up in HIF-PH Market; Evrenzo, Duvroq Neck-and-Neck for Top Spot

With the fifth hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor now launched in Japan, a real showdown has started in what could potentially be a 50-billion yen market for renal anemia (NHI price basis). This number could further grow if these...read more